Secretaría de Salud

🇲🇽Mexico

Country: 🇲🇽Mexico

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia

Not Applicable

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Metformin

First Posted Date: 2017-04-18

Last Posted Date: 2017-07-06

Lead Sponsor: Hospital General de Mexico

Target Recruit Count: 102

Registration Number: NCT03118128

Allergic Rhinitis, Immunotherapy and Vitamin d

Phase 2

Conditions: Allergy

Interventions: Drug: placebo
Drug: Vitamin D3

First Posted Date: 2016-04-14

Last Posted Date: 2016-04-14

Lead Sponsor: Hospital General de Mexico

Target Recruit Count: 60

Registration Number: NCT02738619

Locations: 🇲🇽
Juan Carlos Fernandez de Cordova Aguirre, Ciudad de Mexico, Mexico

Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis

Phase 3

Withdrawn

Conditions: Non-alcoholic Steatohepatitis

Interventions: Other: placebo
Drug: metadoxine

First Posted Date: 2015-09-04

Last Posted Date: 2024-03-15

Lead Sponsor: Hospital General de Mexico

Registration Number: NCT02541045

Locations: 🇲🇽
Hospital General de México, Mexico City, DF, Mexico

Metadoxine as a Therapy for Severe Alcoholic Hepatitis

Phase 4

Completed

Conditions: Severe Alcoholic Hepatitis

Interventions: Drug: Pentoxifylline plus Metadoxine
Drug: Prednisone plus Metadoxine

First Posted Date: 2014-06-12

Last Posted Date: 2014-11-11

Lead Sponsor: Hospital General de Mexico

Target Recruit Count: 135

Registration Number: NCT02161653

Locations: 🇲🇽
Hospital General de Mexico, Mexico City, D.f., Mexico

Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding

Phase 4

Completed

Conditions: Hepatic Encephalopathy

Interventions: Drug: Lactulose
Drug: L-ornithine L-aspartate
Drug: Rifaximin
Drug: Placebo

First Posted Date: 2014-06-06

Last Posted Date: 2018-05-22

Lead Sponsor: Hospital General de Mexico

Target Recruit Count: 88

Registration Number: NCT02158182

Locations: 🇲🇽
Hospital General de Mexico, Mexico City, Mexico

Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies

Phase 2

Completed

Conditions: Spondylarthropathies

Interventions: Drug: Placebo
Drug: infliximab

First Posted Date: 2008-01-11

Last Posted Date: 2008-01-17

Lead Sponsor: Hospital General de Mexico

Target Recruit Count: 26

Registration Number: NCT00591201

Locations: 🇲🇽
Servicio de Reumatología, Hospital General de México, México City, DF, Mexico

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy